Robert Goeltz C.'s Insider Trades & SAST Disclosures
Robert Goeltz C.'s most recent trade in Arcus Biosciences Inc was a trade of 150,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on Jan. 23, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Robert Goeltz C..To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Arcus Biosciences Inc | Robert C. Goeltz | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 150,000 | 150,000 | - | - | Stock Option (right to buy) | |
| Arcus Biosciences Inc | Robert C. Goeltz | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 37,000 | 97,138 (0%) | 0% | 0 | Common Stock | |
| Arcus Biosciences Inc | Robert C. Goeltz | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 15.00 per share. | 31 Dec 2024 | 3,594 | 60,138 (0%) | 0% | 15 | 53,910 | Common Stock |
| Arcus Biosciences Inc | Robert C. Goeltz | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.08 per share. | 15 Dec 2024 | 10,099 | 63,732 (0%) | 0% | 16.1 | 162,392 | Common Stock |
| Arcus Biosciences Inc | Goeltz Robert C. | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 86,600 | 86,600 | - | - | Stock Option (right to buy) | |
| Arcus Biosciences Inc | Robert C. Goeltz | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 22,000 | 73,831 (0%) | 0% | 0 | Common Stock | |
| Arcus Biosciences Inc | Goeltz Robert C. | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 21,300 | 73,131 (0%) | 0% | 0 | Common Stock | |
| Arcus Biosciences Inc | Robert Goeltz C. | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 02 Jan 2024 | 2,004 | 51,831 (0%) | 0% | 20 | 40,080 | Common Stock |
| Arcus Biosciences Inc | Goeltz C. Robert | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 18.09 per share. | 18 Dec 2023 | 2,808 | 53,835 (0%) | 0% | 18.1 | 50,797 | Common Stock |
| Arcus Biosciences Inc | Robert C. Goeltz | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 17.74 per share. | 18 Dec 2023 | 2,749 | 56,643 (0%) | 0% | 17.7 | 48,767 | Common Stock |
| Arcus Biosciences Inc | Robert C. Goeltz | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 20.04 per share. | 07 Jun 2023 | 4,049 | 59,392 (0%) | 0% | 20.0 | 81,142 | Common Stock |
| Arcus Biosciences Inc | Robert C. Goeltz | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2023 | 138,200 | 138,200 | - | - | Stock Option (right to buy) | |
| Arcus Biosciences Inc | Robert C. Goeltz | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2023 | 34,000 | 63,441 (0%) | 0% | 0 | Common Stock | |
| Arcus Biosciences Inc | Robert C. Goeltz | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 30.66 per share. | 16 Dec 2022 | 2,066 | 11,953 (0%) | 0% | 30.7 | 63,344 | Common Stock |
| Arcus Biosciences Inc | Robert C. Goeltz | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 31.23 per share. | 16 Dec 2022 | 387 | 11,566 (0%) | 0% | 31.2 | 12,086 | Common Stock |
| Arcus Biosciences Inc | Robert C. Goeltz | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2022 | 62,500 | 62,500 | - | - | Stock Option (right to buy) | |
| Arcus Biosciences Inc | Robert C. Goeltz | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2022 | 15,500 | 22,519 (0%) | 0% | 0 | Common Stock | |
| Arcus Biosciences Inc | Robert C. Goeltz | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 39.59 per share. | 16 Dec 2021 | 354 | 7,771 (0%) | 0% | 39.6 | 14,015 | Common Stock |
| Arcus Biosciences Inc | Robert C. Goeltz | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 41.42 per share. | 16 Dec 2021 | 224 | 7,019 (0%) | 0% | 41.4 | 9,279 | Common Stock |
| Arcus Biosciences Inc | Robert C. Goeltz | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 40.57 per share. | 16 Dec 2021 | 171 | 7,243 (0%) | 0% | 40.6 | 6,938 | Common Stock |
| Arcus Biosciences Inc | Robert C. Goeltz | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 38.79 per share. | 16 Dec 2021 | 138 | 7,502 (0%) | 0% | 38.8 | 5,353 | Common Stock |
| Arcus Biosciences Inc | Robert C. Goeltz | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 40.46 per share. | 16 Dec 2021 | 131 | 7,640 (0%) | 0% | 40.5 | 5,300 | Common Stock |
| Arcus Biosciences Inc | Robert C. Goeltz | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 39.67 per share. | 16 Dec 2021 | 88 | 7,414 (0%) | 0% | 39.7 | 3,491 | Common Stock |
| Arcus Biosciences Inc | Robert C. Goeltz | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2021 | 75,000 | 75,000 | - | - | Stock Option (right to buy) | |
| Arcus Biosciences Inc | Robert C. Goeltz | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2021 | 12,500 | 17,500 (0%) | 0% | 0 | Common Stock | |
| Arcus Biosciences Inc | Robert C. Goeltz | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 21.57 per share. | 09 Sep 2020 | 5,000 | 5,000 (0%) | 0% | 21.6 | 107,849 | Common Stock |
| Arcus Biosciences Inc | Robert C. Goeltz | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Aug 2020 | 250,000 | 250,000 | - | - | Stock Option (right to buy) | |
| Unity Biotechnology Inc | Robert C. Goeltz | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.67 per share. | 22 Jun 2020 | 2,483 | 161,027 (0%) | 0% | 9.7 | 24,011 | Common Stock, $0.0001 par value |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges